Drug
Lutetium (¹⁷⁷Lu) vipivotide tetraxetan clinical trials
Also written 177Lu-PSMA-617, AAA617, Pluvicto and Lutetium Lu 177 Vipivotide Tetraxetan.
- studies test it
- 47
- open now
- 25
- in phase 3
- 6
- first study started
- 2016
Keep track of what changes. Save the lutetium (¹⁷⁷Lu) vipivotide tetraxetan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2025 (12)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 10 |
| 2025 | 12 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 30
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 39
Novartis Pharmaceuticals (6) · Peter MacCallum Cancer Centre, Australia (3) · University of California, San Francisco (3) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (2) · Dana-Farber Cancer Institute (2) · Weill Medical College of Cornell University (2) · Radboud University Medical Center (2)
Often tested with
Tested in the same studies.
Carboplatin (3) · Cabazitaxel (3) · Pembrolizumab (2) · Abiraterone Acetate (2) · Abiraterone (2) · Prednisone (2) · Gallium 68 PSMA-11 (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses lutetium (¹⁷⁷Lu) vipivotide tetraxetan is read from its arms, and is right about nine times in ten.
Testing it · 47
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingPhase 3Novartis PharmaceuticalsNCT05939414Written as AAA617
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialRecruitingPhase 2University of WashingtonNCT07698535Written as Lutetium Lu 177 Vipivotide Tetraxetan
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate CancerRecruitingPhase 2Maria Sklodowska-Curie National Research Institute of OncologyNCT06449781Written as Lutetium (177Lu) vipivotide tetraxetan
- Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 1University of Michigan Rogel Cancer CenterNCT07682649Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNot yet recruitingPhase 2Emory UniversityNCT07860554Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerRecruitingPhase 2Case Comprehensive Cancer CenterNCT06738303Written as Lu-PSMA-617
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingPhase 2Mayo ClinicNCT07650240Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate AdenocarcinomaRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07150715Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingPhase 2University of California, San FranciscoNCT05766371Written as 177Lu-PSMA-617
- Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617RecruitingPhase 1Thomas HopeNCT07054346Written as 177 Lutetium Prostate-Specific Membrane Antigen 617
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06145633Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingPhase 1/2Vadim S KoshkinNCT05113537Written as Lutetium Lu 177-PSMA-617
- Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseRecruitingPhase 2University of WashingtonNCT06526299Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT06783348Written as 177Lu-PSMA-617
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruitingPhase 4Novartis PharmaceuticalsNCT05803941Written as AAA617
- A Study of 177Lu-PSMA-617 in People With GliomasRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07223034Written as 177Lu-PSMA-617
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate CancerRecruitingPhase 1University of California, San FranciscoNCT07145177Written as 177Lu-PSMA-617
- STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate CancerRecruitingPhase 1/2Angela Y. Jia, MD PhDNCT06574880Written as Lu-PSMA-617
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT06288113Written as Lutetium Lu 177 Vipivotide Tetraxetan
See all 47 studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan →
Given in every arm · 12 — lutetium (¹⁷⁷Lu) vipivotide tetraxetan is usual care beside what is tested
- Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07200830Written as Lutetium Lu 177 Vipivotide Tetraxetan
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT06095089Written as Lutetium Lu-177 Vipivotide Tetraxetan
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Lutetium Lu-177 vipivotide tetraxetan
- Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerRecruitingPhase 1Weill Medical College of Cornell UniversityNCT04886986Written as 177Lu-PSMA-617
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1City of Hope Medical CenterNCT07219147Written as Lutetium Lu 177 Vipivotide Tetraxetan
- Randomized Phase II Trial of Targeted Radiation With no Castration for McrpcRecruitingPhase 2VA Office of Research and DevelopmentNCT06084338Written as Pluvicto
- An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06894511Written as AAA617
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05849298Written as AAA617
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT07047118Written as AAA617
- Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerSuspendedPhase 2Mayo ClinicNCT06200103Written as Lutetium Lu 177 Vipivotide Tetraxetan
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCActive, not recruitingPhase 1/2OncoC4, Inc.NCT05682443Written as lutetium Lu 177 vipivotide tetraxetan
- EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCActive, not recruitingPhase 2Australian and New Zealand Urogenital and Prostate Cancer Trials GroupNCT05150236Written as 177Lu-PSMA-617
As the comparator · 1 — what is tested is compared with lutetium (¹⁷⁷Lu) vipivotide tetraxetan
Codes
What other systems call lutetium (¹⁷⁷Lu) vipivotide tetraxetan · ClinicalTrials.gg INT000522
- MeSH (NLM) C000610110lutetium (177Lu) vipivotide tetraxetanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G6UF363ECXLUTETIUM LU-177 VIPIVOTIDE TETRAXETANConfirmed FDA, NLM, Wikidata
- RxNorm 2597053One source FDA
- Wikidata Q111353661lutetium (¹⁷⁷Lu) vipivotide tetraxetanConfirmed FDA, NLM, Wikidata
- DrugBank DB16778One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000610110 | lutetium (177Lu) vipivotide tetraxetan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G6UF363ECX | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2597053 | — | One source FDA |
| Wikidata | Q111353661 | lutetium (¹⁷⁷Lu) vipivotide tetraxetan | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB16778 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.